Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum

Efficacy was evaluated using real-world data from the EPIK-P1 study
13 Apr 2022
Anticancer agents & Biologic therapy;  Cancer in Special Situations / Population;  Personalised medicine

On 5 April 2022, the US Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice, Novartis Pharmaceuticals) for adult and paediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy.

Efficacy was evaluated using real-world data from the EPIK-P1 (NCT04285723), a single-arm clinical study in patients two years of age and older with PIK3CA-related overgrowth spectrum who received alpelisib as part of an expanded access programme for compassionate use. Eligible patients had clinical manifestations of PIK3CA-related overgrowth spectrum that were assessed by the treating physicians as severe or life-threatening and necessitating systemic treatment and had documented evidence of mutation in the PIK3CA gene. The efficacy of alpelisib was evaluated in a total of 37 patients with at least one target lesion identified on imaging performed within 24 weeks prior to receipt of the first dose.

The major efficacy outcome measure was the proportion of patients with radiological response at week 24 as determined by blinded independent central radiology review, defined as ≥20% reduction from baseline in the sum of measurable target lesion volume in up to 3 lesions confirmed by at least 1 subsequent imaging assessment. Duration of response was an additional efficacy outcome measure. Of the 37 patients included in the efficacy population, 27% (95% confidence interval 14, 44) had a radiological response at week 24. Among responding patients, 60% had a response lasting 12 months or longer.

The most common (≥10%) adverse reactions occurring in patients were diarrhoea, stomatitis, and hyperglycaemia.

The recommended alpelisib dosage for paediatric patients (2 to less than 18 years of age) is 50 mg taken orally once daily with food; for paediatric patients 6 years of age and older, the dose can be increased to 125 mg after 24 weeks if clinically indicated. The recommended dosage for adult patients (≥18 years) is 250 mg taken orally once daily with food.

Full prescribing information for Vijoice is available here.

This review used the Real-Time Oncology Review pilot programme, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, breakthrough designation and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.